Regeneron Pharmaceuticals REGN has outperformed the market over the past 20 years by 14.22% on an annualized basis producing an average annual return of 22.54%. Currently, Regeneron Pharmaceuticals ...

Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...

Biocon Biologics announced a settlement and license agreement with Regeneron for a biosimilar Aflibercept Biocon ... patients across 120+ countries by enabling affordable access to high quality ...

won the top award of $250,000 in the 2025 Regeneron Science Talent Search, the U.S.'s oldest and most prestigious science and math competition for high school seniors. Congratulations to the top ...

Along with resolving site inspection issues that cost Regeneron a high-dose Eylea launch in June, the company has scored an FDA nod for Veopoz as the first treatment for the ultra-rare inherited ...

On Tuesday, Margiano's research resulted in her being selected as one of three Long Island high school finalists in the Regeneron Science Talent Search 2023 competition, the nation's oldest and ...

Taking a near-$6bn hit to top line revenues would damage most companies' valuation, and so it proved with Regeneron. Its share price slid from an April high of $738 to an August low of $580 - a ...

You can convert a low-resolution logo to a high-resolution vector graphic in Photoshop. Photoshop is supposed to be for raster color but here is another surprise, it can also do some amount of ...

The Regeneron Science Talent Search scholars were selected from 1,804 applications received from 603 high schools across 46 states, Washington, D.C., Puerto Rico and eight other countries.

has recommended the synthetic antibody treatment Regeneron for Covid-19, but only in patients with specific health profiles. Those with non-severe Covid-19 who are nonetheless at high risk of ...